ClinicalTrials.gg

Program

deucrictibant

Also written as “Deucrictibant”, “Deucrictibant low dose” and “Deucrictibant high dose”.

Its studies are mostly in Angioedemas, Hereditary, led by Pharvaris Netherlands.

Furthest: phase 3, since Apr 28, 20225 company-led studies, 3 open or runningNext primary completion: Jun 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pharvaris Netherlands53 open or runningphase 3since Apr 28, 2022Sep 7, 2021Jun 2027phase 3 · NCT07266805

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 7, 2021First study: phase 2 study in Angioedemas, HereditaryFirst studyNCT05047185 · 34 enrolled · United States, Austria, Bulgaria and more
  2. Apr 28, 2022Phase 3 study in Angioedemas, HereditaryNCT05396105 · 150 planned · United States, Argentina, Australia and more
  3. Oct 24, 20242 phase 3 studies in Angioedemas, HereditaryNCT06679881, NCT06669754
  4. Oct 20, 2025Phase 3 study in Angioedemas, HereditaryNCT07266805 · 48 planned · United States, Australia, Austria and more

Ahead

  1. Jun 2027Primary completion: phase 3 study in Angioedemas, HereditaryNCT07266805
  2. Jun 2027Primary completion: phase 3 study in Angioedemas, HereditaryNCT05396105
  3. Dec 2028Primary completion: phase 3 study in Angioedemas, HereditaryNCT06679881

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07266805Angioedemas, Hereditary · United States, Australia, Austria and more3RecruitingJun 202748
NCT06679881Angioedemas, Hereditary · United States, Argentina, Australia and more3By invitationDec 2028170
NCT06669754Angioedemas, Hereditary · United States, Argentina, Brazil and more3CompletedJul 21, 202685
NCT05396105Angioedemas, Hereditary · United States, Argentina, Australia and more3By invitationJun 2027150
NCT05047185Angioedemas, Hereditary · United States, Austria, Bulgaria and more2TerminatedJun 30, 202534

How it is read

Names in the registry

  • “Deucrictibant”, 5 entries
  • “deucrictibant”, 2 entries
  • “Deucrictibant low dose”, 1 entry
  • “Deucrictibant high dose”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.